US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated with Alzheimer's disease. Developed by Japanese drug-maker Eisai and comarketed with Biogen Inc (NASDAQ:BIIB), the American pharmaceutical giant, the FDA's endorsement pav
Full Story >>
Vote
+104